Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

PROTAGONIST THERAPEUTICS, INC.

(PTGX)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector news

Health Care Stocks Mixed Premarket Friday

09/17/2021 | 09:13am EDT


ę MT Newswires 2021
All news about PROTAGONIST THERAPEUTICS, INC.
10/26Protagonist Therapeutics Gets $7.5 Million Milestone Payment from Johnson & Johnson's J..
MT
10/26Protagonist Therapeutics Earns $7.5 Million Milestone Payment from IL-23 Receptor Colla..
PR
10/13PROTAGONIST THERAPEUTICS : JMP Securities Adjusts Price Target on Protagonist Therapeutics..
MT
10/13NORTH AMERICAN MORNING BRIEFING : Stock Futures -3-
DJ
10/12PROTAGONIST THERAPEUTICS : Shares Drop on Elevated Volume
MT
10/12PROTAGONIST THERAPEUTICS : JMP Securities Adjusts Price Target on Protagonist Therapeutics..
MT
10/12WALL STREET STOCK EXCHANGE : It's just a period of market normalization
10/12PROTAGONIST THERAPEUTICS : SVB Leerink Adjusts Protagonist Therapeutics' Price Target to $..
MT
10/12PROTAGONIST THERAPEUTICS : JPMorgan Upgrades Protagonist Therapeutics to Overweight From N..
MT
10/12PROTAGONIST THERAPEUTICS : to Present at the Jefferies Next Generation IBD Therapeutics Su..
PR
More news
Analyst Recommendations on PROTAGONIST THERAPEUTICS, INC.
More recommendations
Financials (USD)
Sales 2021 14,2 M - -
Net income 2021 -117 M - -
Net cash 2021 250 M - -
P/E ratio 2021 -12,7x
Yield 2021 -
Capitalization 1 542 M 1 542 M -
EV / Sales 2021 90,7x
EV / Sales 2022 31,4x
Nbr of Employees 101
Free-Float 98,6%
Chart PROTAGONIST THERAPEUTICS, INC.
Duration : Period :
Protagonist Therapeutics, Inc. Technical Analysis Chart | PTGX | US74366E1029 | MarketScreener
Technical analysis trends PROTAGONIST THERAPEUTICS, INC.
Short TermMid-TermLong Term
TrendsNeutralNeutralNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 7
Last Close Price 32,42 $
Average target price 58,29 $
Spread / Average Target 79,8%
EPS Revisions
Managers and Directors
Dinesh V. Patel President, Chief Executive Officer & Director
Donald A. Kalkofen Chief Financial Officer
Harold E. Selick Chairman
Mark L. Smythe Vice President-Technology
David Y. Liu Chief Scientific Officer
Sector and Competitors
1st jan.Capi. (M$)
PROTAGONIST THERAPEUTICS, INC.60.81%1 542
MODERNA, INC.230.95%139 557
LONZA GROUP AG32.63%60 898
IQVIA HOLDINGS INC.42.93%48 923
SEAGEN INC.1.46%32 330
CELLTRION, INC.-38.02%26 036